WALTHAM, Mass., July 15, 2008 (PRIME NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN) (Stockholm:OXGN), a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, today announced the promotion of John A. Kollins to the position of Chief Operating Officer.
